Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 3/2017

01-09-2017 | Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Paronychia. Clinical, Diagnosis and Treatment Aspects

Authors: Martin Arce, Daniela Gutiérrez-Mendoza

Published in: Current Fungal Infection Reports | Issue 3/2017

Login to get access

Abstract

Purpose of Review

The purpose of this study is to recognize and expand the knowledge of mycotic paronychia as a variable clinical condition due to various predisposing factors and multiple fungal organisms.

Recent Findings

Candida-associated mycotic paronychia is common but other non-dermatophyte molds, such as Fusarium, are identified as potential agents of paronychia and onychomycosis.

Summary

Mycotic paronychia is characterized by inflammation of the proximal or lateral nail folds caused by certain fungi. Mycological analysis is necessary to identify the causal agent and prescribe an appropriate treatment. Further studies are needed to know the involved microorganisms in the disease and the pathogenicity factors involved in this localized area of the nail apparatus.
Literature
1.
2.
3.
Daniel CR III, Lorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. Int J Dermatol. 2006a;45(12):1447–8.CrossRefPubMed
4.
5.
Daniel CR 3rd, Daniel MP, Daniel CM, et al. Chronic paronychia and onycholysis: a thirteen-year experience. Cutis. 1996;58(6):397–401.PubMed
6.
Lorizzo M, Piraccini BM, Tosti A. Chronic paronychia: different causes and their treatment. Expert Rev Dermatol. 2006;3(1):375–8.
7.
8.
Hay RJ, Baran R, Moore MK, Wilkinson JD. Candida onychomycosis—an evaluation of the role of Candida species in nail disease. Br J Dermatol. 1988;118(1):47–58.CrossRefPubMed
9.
Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol. 2011;65:1219–27.CrossRefPubMed
10.
Simonetti O, Bernardini ML, Arzeni D, et al. Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years. Mycopathologia. 2004;158:271–4.CrossRefPubMed
11.
12.
Rigopoulos D, Larios G, Gregoriu S. Acute and chronic paronychia. Am Fam Physician. 2008;77(3):339–48.PubMed
13.
Elewsky BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415–29.
14.
Torres-Guerrero E, Arenas R. Onychomycosis: an illustrated guide to diagnosis and treatment. In: Tosti A, Vlahovic TC, Arenas R, editors. Candida onychomycosis. Switzerland: Springer International Publishing; 2017.CrossRef
15.
Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014. Br J Dermatol. 2014;171:937–58.CrossRefPubMed
16.
Tosti A, Piraccini BM, Ghetti E, Colombo MD. Topical steroids versus systemic antifungals in the treatment of chronic paronychia: an open, randomized double-blind and double dummy study. J Am Acad Dermatol. 2002;47(1):73–6.CrossRefPubMed
17.
18.
19.
Daniel CR III, Lorizzo M, Piraccini BM, Tosti A. Grading simple chronic paronychia and onycholysis. J Dermatol. 2006b;45:1447–8.
20.
Dorko E, Jautová J, Pilipcinec E, Tkáciková L. Occurrence of Candida strains in cases of paronychia. Folia Microbiol (Praha). 2004;49(5):591–5.CrossRef
21.
Manzano-Gayosso P, Méndez-Tovar LJ, Arenas R, et al. Levaduras causantes de onicomicosis en cuatro centros dermatológicos mexicanos y su sensibilidad antifúngica a compuestos azólicos. Rev Iberoam Micol. 2011;28(1):32–5.CrossRefPubMed
22.
Fich F, Abarzua-Araya A, Perez M, et al. Candida parapsilosisand Candida guillermondii: emerging pathogens in nail candidiasis. Indian J Dermatol. 2014;59(1):24–9.CrossRefPubMedPubMedCentral
23.
Arendrup MC. Candida and candidemia susceptibility and epidemiology. Dan Med J. 2013;60(11):1–32. B4698
24.
25.
Sardi J, Scorzoni L, Bernardi T, et al. Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62:10–24.CrossRefPubMed
26.
Jayatilake JA, Tilakaratne WM, Panagoda GJ, et al. Candidal onychomycosis: a mini-review. Mycopathologia. 2009;168(4):165–73.CrossRefPubMed
27.
Reyes Delgado K, Staines-Boone AT, Amaya Guerra M, et al. Candidiasis mucocutánea crónica. Dermatol Rev Mex. 2013;57:378–81.
28.
29.
Cano-Pallares C, Ávila-Fuentes AE, Jesús-Silva MA, et al. Piedra blanca y otras infecciones causadas por Trichosporon spp. Dermatol Rev Mex. 2016;60(6):499–507.
30.
Fermin-Goncalves D, Alemán-Mejias E, Colella MT, et al. Estudio de una serie de casos de Tricosporonosis. Dermatol Venez. 2015;53(2):41–5.
31.
Taj-Aldeen SJ, Al-Ansari N, El Shafei S, et al. Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov. J Clin Microbiol. 2009;47(6):1791–9.CrossRefPubMedPubMedCentral
32.
Rizzitelli G, Guanziroli E, Moschin A, et al. Onychomycosis caused by Trichosporon mucoide. Int J Infect Dis. 2016;42:61–3.CrossRefPubMed
33.
34.
Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz HJ. Mycology—an update. Part 1: dermatomycoses: causative agents, epidemiology and pathogenesis. J Dtsch Dermatol Ges. 2014b;12(3):188–209.PubMed
35.
Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–70.PubMed
36.
37.
Lagace J, Cellier E. A case report of a mixed Chaetomium globosum/Trichophyton mentagrophytes onychomycosis. Medl Mycol Case Rep. 2012;1:76–8.CrossRef
38.
Tortorano AM, Richardson M, Roilides E, et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl. 3):27–46.CrossRefPubMed
39.
Muhammed M, Anagnostou T, Desalermos A, et al. Fusarium infection report of 26 cases and review of 97 cases from the literature. Medicine (Baltimore). 2013;92(6):305–16.CrossRefPubMedPubMedCentral
40.
• Al-Hatmi AM, Hagen F, Menken SB, et al. Global molecular epidemiology and genetic diversity of Fusarium, a significant emerging group of human opportunists from 1958 to 2015. Emerg Microbes Infect. 2016;5(12):e124. doi:10.​1038/​emi.​2016.​126. Molecular analyses of Fusaria have revealed medically important and diversity species.CrossRefPubMedPubMedCentral
41.
Motamedi M, Ghasemi Z, Shidfar MR, Hosseinpour L, et al. Growing incidence of non-dermatophyte onychomycosis in Tehran, Iran Jundishapur. J Microbiol. 2016;9(8):e40543. doi:10.​5812/​jjm.​40543.
42.
43.
Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.CrossRefPubMed
44.
Hay RJ, Baran R. Fungal (Onychomycosis) and other infections involving the nail apparatus. In: Baran R, de Berker DAR, Holzberg M, Thomas L, editors. Baran and Dawber’s diseases of the nails and their management. UK: Wiley & Sons; 2012.
45.
Maddy AJ, Abrahams JL, Tosti A. Onychomycoses due to non-dermatophytic molds. In: Tosti A, Vlahovic TC, Arenas R, editors. Onychomycosis: an illustrated guide to diagnosis and treatment. Switzerland: Springer International Publishing; 2017.
46.
Gianni C, Cerri A, Crosti C. “Case report: unusual clinical features of fingernail infection by Fusarium oxysporum Mycoses”.1997; 40: 455–459.
47.
De la Herrán P, López Lozano H, Fierro-Arias L, Ponce Olvera RM, et al. Paroniquia micótica por Fusarium solani: reporte de caso y revisión de la literatura. Dermatología CMQ. 2012;10(2):139–42.
48.
Baran R, Tosti A, Piraccini BM. Uncommon clinical patterns of Fusarium nail infection: report of three cases. Br J Dermatol. 1997;136:424–7.CrossRefPubMed
49.
50.
Bourgeois GP, Cafardi JA, Sellheyer K, Andea AA. Disseminated Fusarium originating from toenail paronychia in a neutropenic patient. Cutis. 2010;85(4):191–4.PubMedPubMedCentral
51.
Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004a;209(2):104–10.CrossRefPubMed
52.
Chiheb S, El Machbouh L, Marnissi F. Paronychia-like cutaneous leishmaniasis. Dermatol Online J. 2015;21(11).
53.
54.
55.
56.
57.
Calderón L, Tirado-Sánchez A, Lázaro-León JM, et al. Frecuencia de alteraciones ungueales secundarias a la administración de taxanos en pacientes mexicanos. Dermatol Rev Mex. 2015;59:493–503.
58.
Lupu I, Voiculescu VM, Bacalbasa N, Prie BE, et al. Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. J Med Life. 2015;8(Special Issue):57–61.PubMedPubMedCentral
59.
Nenoff P, Krüger C, Schaller J. et al. Mycology—an update part 2: dermatomycoses: clinical picture and diagnostics. JDDG. 2014c;1610–0379/2014/1209. doi: 10.​1111/​ddg.​12420.
60.
Migheli Q, Balmas V, Harak H, et al. Molecular phylogenetic diversity of dermatologic and other human patogenic fusarial Isolates from hospitals in northern and central Italy. J Clin Microbiol. 2010a;48(4):1076–84.
61.
Jain S, Seingal VN. Itraconazole versus terbinafine in the management of onychomycosis: an overview. J Dermato Treat. 2003;14:30–42.CrossRef
62.
Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol. 2014;7(7):10–8.PubMedPubMedCentral
63.
64.
65.
Gianni C. Treatment and prevention of paronychia using a new combination of topicals: report of 30 cases. G Ital Dermatol Venereol. 2015;150(4):357–62.PubMed
66.
Gianni C, Romano C. Clinical and histological aspects of toenail onychomycosis caused by Aspergillus spp.: 34 cases treated with weekly intermittent terbinafine. Dermatology. 2004b;209:104–10. doi:10.​1159/​000079593.CrossRefPubMed
67.
Kamalam A, Ajithadass K, Sentamilselvi G, Thambiah AS. Paronychia and black discoloration of a thumb nail caused by Curvularia lunata. Mycopathologia. 1992;118(2):83–4.CrossRefPubMed
Metadata
Title
Fungal Paronychia. Clinical, Diagnosis and Treatment Aspects
Authors
Martin Arce
Daniela Gutiérrez-Mendoza
Publication date
01-09-2017
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 3/2017
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0286-5

Other articles of this Issue 3/2017

Current Fungal Infection Reports 3/2017 Go to the issue

Current Management of Fungal Infections (M Miceli, Section Editor)

Treatment of the Midwestern Endemic Mycoses, Blastomycosis and Histoplasmosis

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Fungal Leukonychia and Melanonychia: a Review

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Antifungal Susceptibility Testing of Candida and Cryptococcus Species and Mechanisms of Resistance: Implications for Clinical Laboratories

Advances in Diagnosis of Invasive Fungal Infections (S Chen, Section Editor)

Volatile Organic Compounds: Upcoming Role in Diagnosis of Invasive Mould Infections

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

Onychomycosis Laboratory Diagnosis: Review

Fungal Infections of Skin and Subcutaneous Tissue (A Bonifaz, Section Editor)

The Efficacy and Safety of Systemic Antifungals in Children’s Onychomycosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits